Milestone Approval of Invasive Brain-Computer I...

By João L. Carapinha

March 20, 2026

China's National Medical Products Administration (NMPA) has approved the world's first invasive brain-computer interface medical device for market entry. Develope...
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solut...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...